Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.27, pp.28-37, 2016. ,
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, vol.362, pp.1273-1281, 2010. ,
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues, Cancer, vol.121, pp.3290-3297, 2015. ,
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer, Br J Cancer, vol.110, pp.2165-2169, 2014. ,
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data, J Exp Clin Cancer Res, vol.34, p.156, 2015. ,
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients, Br J Cancer, vol.116, pp.561-567, 2017. ,
Prediction of survival with secondline therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations, Eur J Cancer, vol.111, pp.94-106, 2019. ,
Second-line chemotherapy in advanced biliary cancer: a systematic review, Ann Oncol, vol.25, pp.2328-2338, 2014. ,
Medical treatment for cholangiocarcinoma, Liver Int, vol.39, issue.1, pp.123-142, 2019. ,
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin, Br J Cancer, vol.119, pp.291-295, 2018. ,
ABC-06 | A randomised phase III, multicentre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC + mFOLFOX) for patients with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. ASCO meeting, 2019. ,
Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data, Crit Rev Oncol Hematol, vol.139, pp.134-142, 2019. ,
A note on quantifying follow-up in studies of failure time, Control Clin Trials, vol.17, pp.343-346, 1996. ,
ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, vol.28, pp.2340-2366, 2017. ,
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol, vol.20, pp.663-673, 2019. ,
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma, Cancer Chemother Pharmacol, vol.77, pp.109-114, 2016. ,
S-1 monotherapy in patients with advanced biliary tract cancer, Oncology, vol.77, pp.71-74, 2009. ,
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine, Invest New Drugs, vol.30, pp.708-713, 2012. ,
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer, Cancer Chemother Pharmacol, vol.71, pp.1141-1146, 2013. ,
FIGHT-202: a phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA), ESMO meeting 2019 Abstract LBA 40 ,
ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. ESMO meeting, 2019. ,
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, N Engl J Med, vol.378, pp.731-739, 2018. ,
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, pp.409-413, 2017. ,
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial, Eur J Cancer, 2017. ,
, 95%CI: 0.701 to 1.250, p=0.6532) (A), subgroup of patients with ECOG, 95%CI: 0.637 to 1.586, p=0.9816 ) (C). Italian (GICO) cohort: overall population
, 95%CI: 0.717 to 1.319 for irinotecan doublet vs. monotherapy, p=0.6846) (A), subgroup of patients with PS 0-1 (HR: 1.007, 95%CI: 0.636 to 1.595 for platinum doublet vs, 95%CI: 0.615 to 1.928 for platinum doublet vs. monotherapy and HR: 0.969, 95%CI: 0.596 to 1.576 for irinotecan doublet vs. monotherapy, p=0.9048) (C). Italian (GICO) cohort: overall population, vol.2